[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:adrenal-gland-pheochromocytoma:somatostatin-receptor":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Adrenal Gland Pheochromocytoma","Somatostatin Receptor",4,[8,16,23,29],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03206060","Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma\u002F Paraganglioma",[12],"Phase 2","RECRUITING","2026-08-26T02:17:45.190188Z","2026-05-05T02:43:27.070855Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06427798","Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma\u002FParaganglioma Previously Treated With Systemic Targeted Radioligand Therapy",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:45.196599Z","2026-07-05T05:32:16.752853Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05636618","Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors",[20],"2026-08-26T02:17:03.534765Z","2026-07-05T05:32:16.808808Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06479811","[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma\u002FParagangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers",[33],"Phase 1","2026-08-26T02:17:34.833510Z","2026-05-05T02:43:28.023362Z"]